CARB-X

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Spexis AG is a clinical-stage biopharmaceutical company based in Switzerland that specializes in the discovery and development of antibiotics and other specialized pharmaceutical products aimed at severe or life-threatening diseases. Founded in 1996, the company is focused on addressing high unmet medical needs, particularly in the realm of antibiotic resistance and severe respiratory conditions. Spexis's lead product, murepavadin, is currently in Phase III development, targeting Pseudomonas aeruginosa, which has been classified as a critical priority pathogen by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of respiratory therapeutics.

Spexis AG is a clinical-stage biopharmaceutical company based in Switzerland that specializes in the discovery and development of antibiotics and other specialized pharmaceutical products aimed at severe or life-threatening diseases. Founded in 1996, the company is focused on addressing high unmet medical needs, particularly in the realm of antibiotic resistance and severe respiratory conditions. Spexis's lead product, murepavadin, is currently in Phase III development, targeting Pseudomonas aeruginosa, which has been classified as a critical priority pathogen by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of respiratory therapeutics.

Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon team is advancing several vaccine candidates for the prevention of major infectious diseases.

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, focused on discovering, developing, and commercializing innovative medicines for unmet medical needs. Established in 2017, the company specializes in small molecule therapies and has a diverse clinical pipeline targeting various therapeutic areas, including central nervous system disorders, cardiovascular conditions, immunological diseases, and orphan diseases. Idorsia collaborates with several partners, including Janssen Biotech for the development of aprocitentan, ReveraGen for vamorolone in Duchenne muscular dystrophy, and Hoffman-La Roche for cancer immunotherapy compounds. Additionally, partnerships with Antares Pharma and Neurocrine Biosciences aim to advance self-administered drug delivery systems and treatments for epilepsy, respectively. The company is committed to expanding therapeutic options and improving patient outcomes through its innovative research and development efforts.

Spexis AG is a clinical-stage biopharmaceutical company based in Switzerland that specializes in the discovery and development of antibiotics and other specialized pharmaceutical products aimed at severe or life-threatening diseases. Founded in 1996, the company is focused on addressing high unmet medical needs, particularly in the realm of antibiotic resistance and severe respiratory conditions. Spexis's lead product, murepavadin, is currently in Phase III development, targeting Pseudomonas aeruginosa, which has been classified as a critical priority pathogen by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of respiratory therapeutics.

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, focused on discovering, developing, and commercializing innovative medicines for unmet medical needs. Established in 2017, the company specializes in small molecule therapies and has a diverse clinical pipeline targeting various therapeutic areas, including central nervous system disorders, cardiovascular conditions, immunological diseases, and orphan diseases. Idorsia collaborates with several partners, including Janssen Biotech for the development of aprocitentan, ReveraGen for vamorolone in Duchenne muscular dystrophy, and Hoffman-La Roche for cancer immunotherapy compounds. Additionally, partnerships with Antares Pharma and Neurocrine Biosciences aim to advance self-administered drug delivery systems and treatments for epilepsy, respectively. The company is committed to expanding therapeutic options and improving patient outcomes through its innovative research and development efforts.